Profluent has raised $106 million in new financing in a round co-led by Altimeter Capital and Bezos Expeditions, with additional participation from prior investors including Spark Capital, Insight Partners, and Air Street Capital. The company reports that its total funding now stands at $150 million. The capital will support continued development of large-scale AI systems for protein design and related applications in therapeutics, diagnostics, agriculture, and biomanufacturing.
Profluent focuses on training and deploying high-capacity generative models for de novo protein design. The group has previously published evidence that large language models can generate functional proteins (Nature Biotechnology, 2023) and has reported an AI-designed CRISPR system developed without reliance on naturally occurring scaffolds (Nature, 2025). Additional work has examined scaling relationships in protein-design performance (NeurIPS, 2025). The company’s internal protein dataset, termed the Protein Atlas, now includes more than 115 billion unique sequences.
With this funding, we are accelerating the path from lab breakthroughs to real-world applications, creating bespoke proteins to solve challenges in human health and the environment. Partners are already deploying our technology while our R&D efforts are rapidly expanding the range and depth of our design capabilities. This capital enables Profluent to expand our platform’s capabilities, expand markets, and bring abundance to therapeutics, agriculture, and biomanufacturing.
Ali Madani, Ph.D., Profluent founder and Chief Executive Officer
Profluent states that its foundation models and AI-generated macromolecules are currently in use across both academic and commercial settings. Its open-source gene-editing platform, OpenCRISPR-1, has been adopted by research groups and several pharmaceutical organizations. Commercial partnerships span multiple sectors, including collaborations with Revvity, Corteva Agriscience, the Rett Syndrome Research Trust, and Integrated DNA Technologies. These activities align with a broader trend in which larger models appear to broaden the accessible design space and increase the yield of candidate proteins with potential industrial or clinical utility.
Profluent combines world-class AI, biology and therapeutic development expertise against the backdrop of thriving scaling laws. This positions them not just as a frontier science company, but as the foundation of a massive new industry. Programmable biology opens the largest design space in nature and reaches into multi-trillion-dollar markets, and Profluent is only at the beginning of exploring it.
Jamin Ball, partner at Altimeter Capital
The company reports that it has expanded its design efforts beyond genome editors to encompass antibodies, antigens, enzymes, and additional biologic formats. Early validation with gene editors is described as having reduced perceived development risk as Profluent pursues applications in therapeutic protein engineering. A central aim is to advance an AI-designed therapeutic candidate toward first-in-human evaluation.